Cardiac PET perfusion tracers: current status and future directions.
Cardiac PET perfusion tracers: current status and future directions.
复制标题
DOI：
10.1053/j.semnuclmed.2014.06.011
复制
发表时间：
2014-09
影响因子：
4.9
通讯作者：
Packard RR
中科院分区：
文献类型：
--
作者：
Maddahi J;Packard RR
正电子发射断层扫描（PET）心肌灌注成像（MPI）越来越多地用于冠状动脉疾病（CAD）的无创检测和评估。然而，PET MPI的广泛使用受到当前PET灌注示踪剂的缺点的限制。这些示踪剂的可用性受到现场（15 O水和13 N氨）或附近（13 N氨）回旋加速器或昂贵发电机（82 Rb）的限制。由于82 Rb的半衰期较短，从76秒到15 O水的2.1分钟和13 N氨的10分钟，它们与跑步机运动应激试验结合使用要么是不可能的（82 Rb和15 O水），要么是不实际的（13 N氨）。此外，82 Rb的长正电子范围使得图像分辨率次优，并且其低提取限制了其缺陷分辨率。近年来，18F标记的PET灌注示踪剂的开发引起了相当大的兴趣。18F的半衰期较长（108分钟），将使示踪剂可作为单位剂量从区域回旋加速器，并允许与跑步机运动试验结合使用。此外，18F的短正电子范围将导致更好的图像分辨率。18F flurpiridaz是迄今为止在动物模型中研究最彻底的，并且是目前正在进行临床评价的唯一基于F18的PET MPI放射性示踪剂。18F氟吡达兹的临床前和临床经验证明了高心肌提取分数、高图像和缺陷分辨率、高心肌摄取、慢心肌清除和高心肌-背景对比度，其随时间稳定-理想PET MPI放射性示踪剂的重要特性。来自其他18F标记的心肌灌注示踪剂的临床前数据令人鼓舞。
Positron emission tomography (PET) myocardial perfusion imaging (MPI) is increasingly used for non-invasive detection and evaluation of coronary artery disease (CAD). However, the widespread use of PET MPI has been limited by shortcomings of the current PET perfusion tracers. Availability of these tracers is limited by need for an on-site (15O water and 13N ammonia) or nearby (13N ammonia) cyclotron or commitment to costly generators (82Rb). Due to short half-lives ranging from 76sec for 82Rb, to 2.1min for 15O water and 10min for 13N ammonia, their use in conjunction with treadmill exercise stress testing is either not possible (82Rb and 15O water) or is not practical (13N ammonia). Furthermore, the long positron range of 82Rb makes image resolution suboptimal and its low extraction limits its defect resolution. In recent years, development of an 18F labeled PET perfusion tracer has gathered considerable interest. The longer half-life of 18F (108 minutes) would make the tracer available as a unit dose from regional cyclotrons and allow use in conjunction with treadmill exercise testing. Furthermore, the short positron range of 18F would result in better image resolution. 18F flurpiridaz is by far the most thoroughly studied in animal models, and is the only F18-based PET MPI radiotracer currently undergoing clinical evaluation. Pre-clinical and clinical experience with 18F flurpiridaz demonstrated a high myocardial extraction fraction, high image and defect resolution, high myocardial uptake, slow myocardial clearance, and high myocardial-to-background contrast which was stable over time – important properties of an ideal PET MPI radiotracer. Pre-clinical data from other 18F labeled myocardial perfusion tracers are encouraging.
登录
查看更多内容
DOI：
10.2967/jnumed.104.007831
发表时间：
2009-07
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
El Fakhri G;Kardan A;Sitek A;Dorbala S;Abi-Hatem N;Lahoud Y;Fischman A;Coughlan M;Yasuda T;Di Carli MF
通讯作者：
Di Carli MF
影响因子：
37.8
作者：
CZERNIN, J;MULLER, P;SCHELBERT, HR
通讯作者：
SCHELBERT, HR
影响因子：
37.8
作者：
BERGMANN, SR;HACK, S;SOBEL, BE
通讯作者：
SOBEL, BE
影响因子：
4.7
作者：
Kim, Dong-Yeon;Kim, Hee-Jung;Min, Jung-Joon
通讯作者：
Min, Jung-Joon
影响因子：
3.1
作者：
Kim, Dong-Yeon;Kim, Hee-Jung;Min, Jung-Joon
通讯作者：
Min, Jung-Joon